(NASDAQ: XGN) Exagen's forecast annual revenue growth rate of 11.52% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.64%.
Exagen's revenue in 2025 is $63,599,000.On average, 9 Wall Street analysts forecast XGN's revenue for 2025 to be $1,540,252,197, with the lowest XGN revenue forecast at $1,470,291,211, and the highest XGN revenue forecast at $1,637,182,272. On average, 9 Wall Street analysts forecast XGN's revenue for 2026 to be $1,775,359,186, with the lowest XGN revenue forecast at $1,665,511,146, and the highest XGN revenue forecast at $1,929,876,195.
In 2027, XGN is forecast to generate $1,995,531,193 in revenue, with the lowest revenue forecast at $1,878,952,212 and the highest revenue forecast at $2,155,940,608.